Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Cardinal Health (CAH) scores highly (85%) based on their Shareholder Yield Investor model, which is based on Meb Faber's strategy of identifying companies returning cash to shareholders through dividends, buybacks, and debt paydown; the report highlights that CAH passes tests for net payout yield, quality and debt, valuation, and relative strength, but fails the shareholder yield test itself.

Analysis

Cardinal Health (CAH), a large-cap growth stock within the Major Drugs industry, scores a notable 85% according to Validea's Shareholder Yield Investor model, which is based on Meb Faber's strategy prioritizing companies that return cash to shareholders via dividends, buybacks, and debt paydown. This high score, indicating model interest, is supported by CAH passing criteria for Net Payout Yield, Quality and Debt, Valuation, and Relative Strength. However, the report also indicates that CAH fails the specific "Shareholder Yield" test, a key metric usually associated with this investment strategy, suggesting that while overall cash return mechanisms may be viewed positively through other lenses (like Net Payout Yield), this particular composite measure is not met. The article notes that not all criteria are equally weighted, which could explain the high overall score despite this specific failure. The sentiment from this report is strongly positive for CAH (0.75 score), though its broader market impact is considered low (0.3).

Key Decisions for Investors

• Investors should investigate the detailed components and weighting of Validea's "Shareholder Yield" test for CAH to understand why it failed this specific criterion despite a high overall score in a model that ostensibly favors such yield.
• The positive performance on Net Payout Yield, Quality and Debt, Valuation, and Relative Strength provides a fundamentally sound basis for consideration, particularly for investors valuing cash return and fundamental quality.
• Before committing capital based on this model, reconcile the failed "Shareholder Yield" test with the overall positive assessment and the model's objective of identifying strong shareholder return profiles.